We have located links that may give you full text access.
Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
International Journal of Antimicrobial Agents 2023 November 5
OBJECTIVES: This study investigated a ceftazidime/avibactam (CZA)-resistant K. pneumoniae (NE368), isolated from a patient exposed to CZA, expressing a novel KPC-3 variant, named KPC-109.
METHODS: Antimicrobial susceptibility testing was performed by reference broth microdilution. WGS analysis of NE368 was performed combining a short- and long-reads approach by Illumina and Nanopore technologies. Functional characterization of KPC-109 was performed investigating the impact of KPC-109 production on the β-lactam resistance phenotype of various Escherichia coli and Klebsiella pneumoniae strains, including derivatives of K. pneumoniae with OmpK35 and OmpK36 porin alterations. Horizontal transfer of the KPC-109-encoding plasmid was investigated by conjugation and transformation experiments.
RESULTS: K. pneumoniae NE368 was isolated from a patient after repeated CZA exposure, and showed resistance to CZA, fluoroquinolones, piperacillin-tazobactam, expanded-spectrum cephalosporins, amikacin, carbapenems, and cefiderocol. WGS revealed the presence of a large chimeric plasmid of original structure (pKPN-NE368), encoding a novel 270-loop mutated KPC-3 variant, named KPC-109 (ins_270_KYNKDD). KPC-109 production mediated resistance/decreased susceptibility to avibactam-based combinations (with ceftazidime, cefepime and aztreonam) and cefiderocol, with a trade-off on carbapenem resistance. However, in the presence of porin alterations commonly encountered in high-risk clonal lineages of K. pneumoniae, KPC-109 was able to confer clinical-level resistance to carbapenems as well. Resistance to cefiderocol in NE368 was likely contributed by KPC-109 production acting in concert with a mutated EnvZ sensor kinase. The KPC-109-encoding plasmid was apparently not conjugative.
CONCLUSIONS: Present findings expanded current knowledge about the diversity of emerging KPC enzymes variants with 270-loop alterations that can be encountered in the clinical setting.
METHODS: Antimicrobial susceptibility testing was performed by reference broth microdilution. WGS analysis of NE368 was performed combining a short- and long-reads approach by Illumina and Nanopore technologies. Functional characterization of KPC-109 was performed investigating the impact of KPC-109 production on the β-lactam resistance phenotype of various Escherichia coli and Klebsiella pneumoniae strains, including derivatives of K. pneumoniae with OmpK35 and OmpK36 porin alterations. Horizontal transfer of the KPC-109-encoding plasmid was investigated by conjugation and transformation experiments.
RESULTS: K. pneumoniae NE368 was isolated from a patient after repeated CZA exposure, and showed resistance to CZA, fluoroquinolones, piperacillin-tazobactam, expanded-spectrum cephalosporins, amikacin, carbapenems, and cefiderocol. WGS revealed the presence of a large chimeric plasmid of original structure (pKPN-NE368), encoding a novel 270-loop mutated KPC-3 variant, named KPC-109 (ins_270_KYNKDD). KPC-109 production mediated resistance/decreased susceptibility to avibactam-based combinations (with ceftazidime, cefepime and aztreonam) and cefiderocol, with a trade-off on carbapenem resistance. However, in the presence of porin alterations commonly encountered in high-risk clonal lineages of K. pneumoniae, KPC-109 was able to confer clinical-level resistance to carbapenems as well. Resistance to cefiderocol in NE368 was likely contributed by KPC-109 production acting in concert with a mutated EnvZ sensor kinase. The KPC-109-encoding plasmid was apparently not conjugative.
CONCLUSIONS: Present findings expanded current knowledge about the diversity of emerging KPC enzymes variants with 270-loop alterations that can be encountered in the clinical setting.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app